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Abstract
Background: This study was performed to detect risk factors for Pseudomonas aeruginosa bacteremia in patients
with liver cirrhosis.
Methods: A retrospective case–control study was designed to identify risk factors for P. aeruginosa bacteremia in
cirrhotic patients. The cases were cirrhotic patients with P. aeruginosa bacteremia and the controls were cirrhotic
patients with Enterobacteriaceae bacteremia.
Results: Sixty-one cases and the same number of controls were enrolled. In a multivariate analysis, younger age
{adjusted odds ratio (aOR) per one year: 0.96, 95% confidence interval: 0.93 - 0.99}, nosocomial acquisition (aOR 3.87,
95% confidence interval: 1.50 - 9.94), preexisting biliary disease (aOR 4.79, 95% confidence interval: 1.92 - 10.47), and
recent exposure to immunosuppressive agent (aOR 3.10, 95% confidence interval: 1.23 - 7.82) were associated with
P. aeruginosa bacteremia. In the case group the frequency of appropriate initial antibiotic regimens was
considerably lower than in the control group: 29.5% vs. 65.6% (P <0.01). However, thirty day mortality did not differ
significantly between cases and controls (19.7% vs. 24.6%).
Conclusions: Nosocomial acquisition, preexisting biliary disease, and recent use of immunosuppressive agents are
strong predictive factors for P. aeruginosa bacteremia in cirrhotic patients.
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Background
Blood stream infection by Gram negative bacteria is a
common complication in cirrhotic patients, and the prog-
nosis of the bacteremia in this group is poor [1,2]. Third
generation cephalosporins are most commonly used to
treat infectious complications in patients with liver cirrho-
sis, but their antimicrobial spectra against Pseudomonas
aeruginosa are not identical to each other [3-5]. It has
been reported that inadequate or delayed antibiotic ther-
apy for pseudomonas bacteremia is associated with poor
prognosis [6-9]. Hence, empirical antimicrobial therapy
that lacks anti-pseudomonal activity could be harmful in
case of pseudomonas bacteremia.
Thus, it is important for clinicians to be aware of the
risk factors for pseudomonas bacteremia. Neutropenia
following chemotherapy is a well-known risk factor [10],
and some clinical predictors of pseudomonas bacteremia
have been reported in patients without neutropenia
[11-13]. Age over 90 years, healthcare-associated infec-
tion, indwelling central venous catheter, indwelling urin-
ary device, and antimicrobial therapy within the
previous 30 days, have been reported to be clinical pre-
dictors of pseudomonas infection.
However, no studies have focused on the clinical pre-
dictors or outcomes of pseudomonas bacteremia in pa-
tients with liver cirrhosis. The aim of this study was
therefore to identify predictive factors and clinical
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outcomes of pseudomonas bacteremia in patients with
liver cirrhosis.
Methods
Study design and subjects
We performed a case–control study to identify risk factors
associated with pseudomonas bacteremia in cirrhotic pa-
tients. Cirrhosis was diagnosed by gastroenterologists
based on patient history and physical, laboratory, and
radiologic features. Cases were defined as patients with
liver cirrhosis and bacteremia due to P. aeruginosa admit-
ted to Seoul National University Hospital (SNUH) or
Seoul National University Bundang Hospital (SNUBH)
during the period January 2005 through December 2011.
SNUH is a university-affiliated tertiary referral hospital
with 1,600 beds, located in Seoul, Korea. SNUBH is also a
university affiliated tertiary referral hospital and it is lo-
cated in Seong-Nam, Korea. To select controls, we
recruited at random cirrhotic patients with bacteremias
caused by Enterobacteriaceae, who were admitted to
SNUH or SNUBH in the same period. The numbers of
case and control patients were the same. When patients
experienced two or more episodes of bacteremia, we se-
lected the first.
Data collection
We reviewed electronic medical records and following data
have been collected: age, sex, etiology of liver cirrhosis,
liver function measured by Child-Pugh score, severity of
bacteremia measured by Pitt bacteremia score, Charlson
weighted index of comorbidity, associated diseases or
conditions (such as diabetes, renal failure, malignancies,
chronic obstructive pulmonary disease, bronchiectasis,
etc.), primary focus of bacteremia (e.g. primary bacteremia,
urinary tract, biliary tract, vascular catheters, and etc.), po-
tential risk factors of pseudomonas infection (such as
nosocomial or healthcare-associated infection, antibiotic
exposure in recent 30 days, use of corticosteroids or anti-
neoplastic agents, central venous catheter, urinary catheter,
nasogastric tube, neutropenia), laboratory data at the time
of diagnosis of bacteremia (such as serum creatinine, pro-
thrombin time, bilirubin, albumin), adequacy of initial anti-
biotics, and 30-day mortality.
Definitions
Community acquired bacteremia: bacteremia developed
before or in the initial 48 hours of hospitalization and
not due to healthcare-associated bacteremia.
Nosocomial acquisition: nosocomial bacteremia or
healthcare-associated bacteremia. Nosocomial bacteremia
was diagnosed when the bacteremia developed more than
48 hours after admission. We considered it healthcare-
associated if any of the following conditions were present:
1) hemodialysis in the previous 30 days, 2) antibiotic
treatment in the previous 30 days, 3) a history of >
48 hours hospital admission (including nursing home and
long term care facility) in the previous 90 days.
Recent exposure to immunosuppressive drugs: expos-
ure to anti-neoplastic drugs, cytotoxic agents, corti-
costeroids, or monoclonal antibodies used to suppress
the immune system within 30 days of the onset of
bacteremia.
Appropriate antibiotic treatment: at least one anti-
biotic shown to be effective in microbiologic tests ad-
ministrated within 24 hours.
Microbiologic test
The VITEK II automated system (bioMérieux Inc.,
Marcy L’Etoile, France) was used to identify bacterial or-
ganisms. In the VITEK II, system bacterial organisms are
identified with standard identification cards.
Statistics
Student’s t-test was used for normally distributed con-
tinuous variables, and the Wilcoxon rank sum test for
non-normally distributed continuous variables. The Chi-
square or Fisher’s exact test was used to analyze categor-
ical variables. A logistic regression model was adopted
to adjust for confounding variables and to identify risk
factors. To this end, we performed a stepwise multivari-
ate logistic regression analysis. All variables with P <0.1
in the univariate analysis were included in the multivari-
ate analysis, and variables with P <0.05 were selected in
the final model. SAS v9.3 (SAS Institute Inc., Cary, NC,
USA) was used for all statistical analyses.
Study approval
This study was approved by the institutional review
board of the Seoul National University Hospital Medical
Center (Protocol No; H-1201-002-391) according to the




During the study period, a total of 67 episodes of
pseudomonas bacteremia developed in 63 patients, and
739 episodes of Enterobacteriaceae bacteremia in 593
patients. Two patients with polymicrobial bacteremia
caused by P. aeruginosa and Enterobacteriaceae were ex-
cluded. Finally, 61 pseudomonas bacteremia patients
were included as the case group, and 61 control patients
were selected at random from the above 593 patients; in
the latter, Escherichia coli was most common organism
(29/61, 47.5%), followed by Klebsiella pneumoniae (22/
61, 36.1%), Enterobacter cloacae (4/61, 6.6%), Citrobacter
freundii (2/61, 3.3%), Enterobacter aerogenes (1/61,
1.6%), and Salmonella enterica (1/61, 1.6%).
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Predictive factors for P. aeruginosa bacteremia
The mean age (± standard deviation) of the case group
was slightly lower than that of the control group: 56.8 ±
13.1 and 60.7 ± 8.9, respectively (Table 1). Males
predominated in both groups. Biliary origin was more
common in the case group (52.5% vs. 26.3%, P <0.01), as
was nosocomial acquisition (83.6% vs. 54.1%, P < 0.01).
Neither the severity of cirrhosis measured by Child-
Pugh class nor the severity of comorbid conditions mea-
sured by Charlson weighted index or the severity of
bacteremia measured by Pitt bacteremia score differed
between the two groups. Liver transplantation was
performed more frequently in the case group (32.8% vs.
16.4%, P = 0.04), and preexisting biliary disease was also
more common (63.9% vs. 29.5%, P <0.01), as was the use
of immunosuppressive drugs (39.3% vs. 18.0%, P <0.01).
Age, etiology of liver cirrhosis, onset of bacteremia
(community onset vs. nosocomial acquisition), liver trans-
plantation, preexisting biliary disease, acute renal failure,
recent exposure to immunosuppressive drug, and pro-
thrombin time were selected for the multivariate logistic
regression analysis. After stepwise selection, age, onset of
bacteremia, preexisting biliary disease, and exposure to
immunosuppressive drugs were included in the final
model (Table 2). Age was negatively associated with
P. aeruginosa bacteremia with an adjusted odds ratio
(aOR) of 0.96 (95% confidence interval: 0.93 - 0.99, P =
0.03), and nosocomial acquisition was related to pseudo-
monas bacteremia with aOR 3.87 (95% confidence inter-
val: 1.50 - 9.94, P < 0.01). Preexisting biliary disease was
strongly related to pseudomonas bacteremia (aOR 4.79,
95% confidence interval: 1.92 - 10.47, P <0.01), as was re-
cent exposure to immunosuppressive drugs (aOR: 3.10,
95% confidence interval: 1.23 - 7.87, P = 0.02).
Clinical outcomes and the impact of inadequate antibiotics
In the case group the frequency of appropriate initial
antibiotic regimens was considerably lower than in the
control group: 29.5% vs. 65.6% (P <0.01). However, 30-
day mortality did not differ: 12/61 (19.7%) in the case
group, 15/61 (24.6%) in the control group (P = 0.51). In
the case group, 18/61 (29.5%) of the patients received
adequate initial antibiotic therapy. Of these, eleven re-
ceived beta-lactam antibiotics, and seven, quinolones.
The clinical characteristics and outcomes in the case
group according to adequacy of empirical antibiotics are
shown in Table 3. 30-day mortality was lower in the pa-
tients who were prescribed adequate initial antibiotic
agent(s) than in those who were not, (11.1% vs. 23.3%),
but the difference was not significant (P = 0.48).
Discussion
In this study, nosocomial acquisition was an important
predictor of pseudomonas bacteremia with aOR 3.87
(95% confidence interval: 1.50 - 9.94, P <0.01). P.
aeruginosa is a significant cause of infection in patients
exposed to hospital environments; the second most
common cause of nosocomial pneumonia, and the third
most common cause of nosocomial urinary tract infec-
tion [14]. Thus this finding is plausible, and consistent
with previous reports [11,13,15,16].
It is notable that pseudomonas bacteremia was signifi-
cantly associated with the presence of biliary disease in
cirrhotic patients, with aOR 4.79 (95% confidence inter-
val: 1.92 - 10.47, P <0.01). P. aeruginosa is one of the
most frequent etiologic organisms of bacteremic biliary
tract infection [17-19]. In our study, 33 of the 39 case
patients with biliary tract disease had preexisting biliary
catheters, including percutaneous transhepatic biliary
drains, endoscopic retrograde biliary drains, and endo-
scopic nasobiliary drains. P. aeruginosa can form firm
biofilms on foreign material and cause foreign material-
associated infections [14,20,21]. Thus biliary catheters
may play a role in the origin of biliary sepsis involving P.
aeruginosa in patients with biliary diseases, and the re-
sults of previous studies support this notion [22-24].
Twenty of the 61 (32.8%) patients with pseudomonas
bacteremia had received liver transplants. During such
operations, biliary-to-biliary anastomosis is made, and
biliary catheters are frequently used. This suggests that
clinicians should consider prescribing empirical antibi-
otics with anti-pseudomonas activity when gram nega-
tive bacteremia develops in cirrhotic patients with biliary
diseases or preexisting biliary catheters.
It is well known that immune deficiency conditions,
such as HIV infection, neutropenia, and use of immuno-
suppressive agents, are risk factors for pseudomonas in-
fection [14]. Recent use of immunosuppressive agents
was also associated with pseudomonas bacteremia in
this study. We found that the mean age of patients
with pseudomonas bacteremia was lower than that of
patients with Enterobacteriaceae bacteremia. However
the difference was too small to have clinical signifi-
cance (aOR: 0.96, 95% confidence interval: 0.93 -
0.99, P = 0.03).
Inappropriate antibiotic therapy is known to result
in poor prognoses in P. aeruginosa bacteremia
[6-9,12,25,26]. In our study, inappropriate initial antibi-
otics were prescribed more frequently in the case group,
but mortality was similar in the two groups. We think
that the difference between our findings and previous
ones may be due to differences in the study populations:
in the earlier studies, pneumonia, non-hepatobiliary tract
origin, presence of neutropenia, and initial presentation
with septic shock, were prognostic factors for poor out-
comes in patients with pseudomonas bacteremia [7,11].
In our study, the most common source of bacteremia
was the biliary tract, and only a small proportion of the
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Table 1 Baseline and clinical characteristics of 61 cirrhotic patients with Pseudomonas aeruginosa bacteremia and 61
controls with Enterobacteriaceae bacteremia
Variable Case patients Control patients P
(n = 61) (n = 61)
Age (mean in year ± SD) 56.8 ± 13.1 60.7 ± 8.9 0.06
Male (%) 46 (75.4) 44 (72.1) 0.68
Etiology of liver cirrhosis (%) 0.10
HBV 41 (67.2) 44 (72.1)
HCV 6 (9.8) 11 (18.0)
Alcohol 1 (1.6) 2 (3.3)
Cryptogenic 11 (18.0) 4 (6.6)
Biliary 2 (3.3) 0 (0.0)
Source of bacteremia (%) <0.01
Lung 4 (6.6) 1 (1.6)
Urinary tract 1 (1.6) 6 (9.8)
CVC 0 (0.0) 0 (0.0)
SBP 6 (9.8) 19 (31.2)
Biliary tree 32 (52.5) 16 (26.3)
Abdomena 7 (11.5) 3 (4.9)
Other 2 (3.3) 1 (1.6)
Unknown 9 (14.8) 15 (24.6)
Onset of bacteremia (%) <0.01
Community acquired 10 (16.4) 28 (45.9)
Nosocomialb 51 (83.6) 33 (54.1)
Child-Pugh class (%) 0.64
A 17 (27.9) 16 (26.2)
B 24 (39.3) 22 (36.1)
C 20 (32.8) 23 (37.7)
Pitt bacteremia score (mean ± SD) 2.0 ± 2.6 1.4 ± 1.9 0.14
Charlson weighted index of comorbidity (mean ± SD) 5.7 ± 1.9 5.2 ± 1.7 0.16
Comorbid conditions (%)
Liver transplantation 20 (32.8) 10 (16.4) 0.04
Biliary disease 39 (63.9) 18 (29.5) <0.01
Diabetes mellitus 4 (6.6) 5 (8.2) 1.00
End stage renal disease 5 (8.2) 4 (6.6) 1.00
Hepatocellular carcinoma 40 (65.6) 38 (62.3) 0.71
Solid tumor other than HCC 8 (13.1) 4 (6.6) 0.36
Hematologic malignancies 3 (4.7) 0 (0.0) 0.24
Chronic obstructive pulmonary disease 1 (1.6) 0 (0.0) 1.00
Bronchiectasis 2 (3.3) 0 (0.0) 0.50
Clinical presentation (%)
Fever 51 (83.6) 49 (80.3) 0.64
Acute renal failure 0 (0.0) 6 (9.8) 0.03
Septic shock 5 (8.2) 7 (11.5) 0.54
Co-existing conditions (%)
Neutropenia 2 (3.3) 0 (0.0) 0.50
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patients had neutropenia. Our mortality findings are
similar to those of Joo et al., who found similar mortality
in pseudomonas bacteremia and Enterobacteriaceae
bacteremia [11]. In that study the pseudomonas
bacteremia originated from biliary tract infections in
50% of the patients. It is well known that interventions
to relieve biliary tree obstruction are the mainstay of
treatments for biliary tree infection [14].
As far as we know, this is the first study examining the
clinical predictors of pseudomonas bacteremia in cirrhotic
patients. It has several limitations. First, it is a retrospect-
ive study, and there may be unidentified confounding fac-
tors. Second, although we enrolled patients in two tertiary
hospitals over seven years, the study population was rela-
tively small, and we could not assess the significance of
small differences. Third, control group was more hetero-
geneous than the case group, because the control group
included patients infected with a variety of species of the
family Enterobacteriaceae.
Conclusions
Nosocomial acquisition, biliary disease, and exposure to
immunosuppressive agents are significantly related to
P. aeruginosa bacteremia in cirrhotic patients, compa-
red to cirrhotic patients with bacteremia caused by
Entrobacteriaceae.
Table 1 Baseline and clinical characteristics of 61 cirrhotic patients with Pseudomonas aeruginosa bacteremia and 61
controls with Enterobacteriaceae bacteremia (Continued)
Immunosuppressive drugc 24 (39.3) 11 (18.0) <0.01
CVC 2 (3.3) 6 (9.8) 0.27
Urinary catheter 2 (3.3) 5 (8.2) 0.44
Nasogastric tube 2 (3.3) 3 (4.9) 1.00
Previous exposure of antibiotics (%) 52 (85.3) 50 (82.03) 0.47
Polymicrobial bacteremia (%) 5 (8.2)d 2 (3.3)e 0.44
Laboratory data at the time of bacteremia
Bilirubin (mg/dL), median (IQR) 3.7 (1.2 - 13.4) 2.2 (1.4 - 5.5) 0.34
Prothrombin time (by INR), median (IQR) 1.29 (1.11 - 1.56) 1.43 (1.21 - 1.70) 0.02
Albumin (g/dL), median (IQR) 3.1 (2.8 - 3.8) 3.0 (2.6 - 3.4) 0.30
Creatinine (mg/dL), median (IQR) 1.00 (0.81 - 1.56) 1.00 (0.90 - 1.40) 0.50
Appropriate initial antibiotic regimen (%) 18 (29.5) 40 (65.6) <0.01
30-day mortality (%) 12 (19.7) 15 (24.6) 0.51
aIntra-abdominal infection excluding SBP and biliary tree infection.
bIncludes both nosocomial bacteremia and healthcare-associated bacteremia.
cIncludes anti-neoplastic drugs, cytotoxic drugs, and corticosteroids.
dAssociated bacteria were Enterococcus faecalis (2), Enterococcus faecium (1), Enterococcus gallinarum (1), Staphylococcus epidermis (1).
eAssociated bacteria were Salmonella enterica + E. faecium (1), Serratia liquefaciens + Enterobacter cloacae (1).
Abbreviation: SD standard deviation, HBV hepatitis B virus, HCV hepatitis C virus, CVC central venous catheter, SBP spontaneous bacterial peritonitis, IQR
interquartile range, HCC hepatocellular carcinoma, INR international normalized ratio.
Table 2 Independent factors associated with
Pseudomonas aeruginosa bacteremia in cirrhotic patients
on the basis of a multivariate logistic regression analysisa
Variable Adjusted odd ratios (95% CI) P
Age 0.96 (0.93 - 0.99) 0.03
Nosocomial acquisitionb 3.87 (1.50 - 9.94) <0.01
Biliary disease 4.79 (1.92 - 10.47) <0.01
Immunosuppressive drug 3.10 (1.23 - 7.82) 0.02
aVariables with P <0.1 in the univariate analysis were included in the
multivariate logistic regression analysis.
bIncludes both nosocomial bacteremia and healthcare-associated bacteremia.
Abbreviation: CI confidence interval.
Table 3 Outcomes and impact of inadequate antibiotics
among 61 cirrhotic patients with Pseudomonas aeruginosa
bacteremia





Age (mean in year, SD) 49.1 ± 15.5 60.0 ± 10.5 0.01
Male (%) 13 (72.2) 33 (76.7) 0.75
Child-Pugh score (mean ± SD) 7.1 ± 2.1 8.7 ± 2.4 0.02
Pitt bacteremia score (mean ± SD) 1.3 ± 1.9 2.3 ± 2.9 0.18
30-day mortality (%) 2 (11.1) 10 (23.3) 0.48
Abbreviation: SD standard deviation, IQR interquartile range.
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